Disturbance of neurotransmitter metabolites in peripheral blood of schizophrenia patients treated with olanzapine: a preliminary targeted metabolomic study.

ABSTRACT:

Background

The aim of this research was to characterize changes in peripheral blood neurotransmitter metabolites in olanzapine-treated schizophrenia (SCZ) and to identify potential biomarkers for SCZ. Concurrently, the relationship between these differential neurotransmitters and cognitive function is explored.

Methods

We recruited 40 SCZ treated with single-agent olanzapine and 40 healthy controls (HC). Cognitive function and psychopathology were assessed using the MCCB and PANSS, respectively. Neurotransmitter levels were determined by targeted metabolomics approach using liquid chromatography-mass spectrometry (LC/MS).

Results

SCZ showed cognitive impairment in all domains of the MCCB compared to HC. Interestingly, a 4-neurotransmitter panel consisting of 3-Methoxy

SUBMITTER: Yin J 

PROVIDER: S-EPMC11837362 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature